✦ LIBER ✦

Efficacy, safety and tolerability of rasagiline as an add-on therapy to dopamine agonists in early Parkinson's disease: The ANDANTE study

✍ Scribed by Isaacson, S.; Silver, D.; Choudhry, A.; Hauser, R.A.

Book ID: 123593870
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 78 KB
Volume: 333
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2013.07.571

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term efficacy and safety of safinam

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

✍ A. H. V. Schapira; F. Stocchi; R. Borgohain; M. Onofrj; M. Bhatt; P. Lorenzana; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 548 KB

2.209 Long-term double-blind, placebo-co

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

✍ R. Anand; V. Lucini; R. Guiliani; S. Rossetti 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Cognitive performance in people with Par

Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to l-dopa therapy

✍ I. Rektorová; I. Rektor; M. Bareš; V. Dostál; E. Ehler; Z. Fanfrdlová; J. Fiedle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

Efficacy, safety, and tolerance of the n

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study

✍ Pinter, M M; Pogarell, O; Oertel, W H 📂 Article 📅 1999 🏛 BMJ Publishing Group 🌐 English ⚖ 195 KB

Efficacy, safety, and tolerability of ov

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

✍ Olivier Rascol; Paolo Barone; Robert A. Hauser; Yoshikuni Mizuno; Werner Poewe; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

## Abstract The aim of this article is to test the feasibility, in early Parkinson's disease (PD), of an overnight switch from immediate‐release (IR) pramipexole to a new once‐daily extended‐release (ER) formulation. Nonfluctuating patients on pramipexole IR three‐times daily, alone or with levodop

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to